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Syncope is a common condition. It is frequently
due to a benign cause, but may occasionally be due
to a potentially life-threatening disorder. The pres-
ence of structural heart disease in patients with
syncope is associated with a poor prognosis and
may be a predictor of sudden cardiac death. In
patients who present with syncope, the presence of
structural heart disease and primary electrophys-
iological disorders should be considered and fur-
ther cardiac evaluation performed as indicated by
the clinical history, physical examination and
electrocardiographic findings.
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Introduction
Syncope is defined as a sudden, but transient loss
of consciousness accompanied by a loss of postural
tone. Recovery is spontaneous and does not
require the use of cardiopulmonary resuscitation.
Syncope is a common condition and the differential
diagnosis is extensive. It has been reported that the
frequency of syncope amongst users of emergency
departments in Europe is approximately 1% [1, 2].
The causes of syncope are frequently benign, but
can occasionally be due to a potentially life-threat-
ening disorder [3]. Because of the transient nature
of syncope and some of its causes, determination of
the underlying mechanism can be challenging. A
comprehensive initial clinical history along with a
detailed physical examination and an electrocar-
diogram (ECG) are essential for determining the
possible causes as well as the need for further
diagnostic testing. However, despite a thorough
evaluation, the cause of syncope may remain
unknown in approximately a third of patients.
The causes of syncope are heterogeneous and vary
with age (Table 1). Neurocardiogenic (vasovagal)
syncope is most common in patients under the age
of 40 years and usually has a favourable prognosis
[4]. More serious, but less frequent causes of
syncope in those under the age of 40 include
hypertrophic cardiomyopathy and the so-called
primary electrophysiological disorders, which can
result in ventricular tachycardia (VT) and fibrilla-
tion [5]. In individuals over the age of 40 years,
cardiac mechanical causes, such as heart failure
and aortic stenosis, in addition to arrhythmias are
more common [6]. Furthermore, conditions such
as orthostatic hypotension and drug-related syn-
cope are not uncommon in older age groups. In the
elderly, syncope is also more commonly due to a
combination of factors. The presence of structural
heart disease increases the likelihood of a serious
cause of syncope, such as malignant ventricular
arrhythmias.
There are two main goals in the evaluation of
patients with syncope. The first aim is to establish
the cause of the syncopal event. Secondly, patients
are stratified according to risk, including identifi-
cation of those at high risk of sudden cardiac death
or of recurrent syncope or physical injury [5, 6].
High-risk features of syncope
Cardiac syncope can predict sudden cardiac death
[7]. Individuals who present with syncope and are
at high risk of subsequent sudden cardiac death,
frequently have a history of structural heart dis-
ease along with clinical or ECG characteristics
suggestive of a serious arrhythmia [6]. These
characteristics include heart failure with a severely
reduced ejection fraction or the presence of myo-
cardial scar tissue from previous myocardial
infarction. Clinical features suggestive of a serious
cause of syncope include occurrence during either
exertion or whilst supine. Prodromal symptoms of
chest pain, acute shortness of breath and palpita-
tions with sudden onset of dizziness may all
suggest a possible serious cardiac cause. A higher
risk of sudden cardiac death is also indicated by an
ECG showing one or more of the following
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abnormalities: nonsustained VT, bifascicular block
or intraventricular conduction delay (QRS > 120
ms), a pre-excited QRS, abnormally prolonged or
short QT interval, a Brugada syndrome pattern or
negative T waves in the precordial leads along with
an epsilon wave consistent with arrhythmogenic
right ventricular cardiomyopathy [6, 8]. Patients
presenting with syncope and one or more of the
above ECG abnormalities are candidates for hos-
pital admission. These individuals should receive
continuous ECG monitoring and further diagnostic
evaluation whilst in hospital; consultation with an
arrhythmia specialist should also be considered.
A diagnosis of a cardiac cause of syncope has
important prognostic implications. Studies com-
paring mortality after syncope according to likely
mechanism have consistently shown that patients
with a cardiac cause have a higher mortality than
those with a noncardiac cause [9]. In the largest
such study of over 400 patients with a follow-up of
more than 60 months, the mortality rate during
follow-up was 50% in patients with a cardiac cause
compared with rates of 31% and 24%, respectively,
in those with a noncardiac or unknown cause [10].
A variety of structural heart diseases can result in
syncope (Table 2) [6]. Disorders commonly associ-
ated with syncope include ischaemic heart disease
(especially if associated with depressed left ven-
tricular function), nonischaemic dilated cardiomy-
opathy and severe aortic stenosis. Other less
frequent, but nevertheless important causes are
hypertrophic cardiomyopathy and arrhythmogenic
right ventricular cardiomyopathy (previously
termed dysplasia). Although not classified as struc-
tural heart diseases, but rather as genetic disor-
ders that underlie primary electrophysiological
disease, the long QT interval syndrome (LQTS),
short QT syndrome, catecholaminergic polymor-
phic VT and Brugada syndrome are also worth
considering as relatively infrequent, but serious
causes of syncope. Similarly, an accessory atrio-
ventricular pathway causing delta wave on the
ECG may represent uncommon causes of severe
syncope. In the latter case, atrial fibrillation can be
associated with extremely high ventricular rates
due to rapid conduction over the accessory path-
way, which may sometimes lead to syncope and
even cardiac arrest.
Myocarditis, pulmonary embolism, cardiac tamp-
onade, atrial myxoma, severe pulmonary hyper-
tension and certain congenital heart diseases
(including those previously repaired) are structural
heart disorders that are occasionally associated
with syncope [6].
A family history of sudden cardiac death, especially
at a young age, should alert to the possibility of an
inherited arrhythmogenic disease [5]. Likewise,
Table 1 Causes of syncope according to age
Patients < 40 years of age Patients  40 years of age
Neurocardiogenica Cardiacc
Psychiatrica Mechanical
Long QT syndromeb Arrhythmic
(tachy- or
bradyarrhythmias)
Brugada syndromeb Orthostatic hypotensiona
Wolf–Parkinson–White
syndromeb
Drug relateda
Arrhythmogenic right
ventricular
cardiomyopathyb
Multifactoriala
Ventricular
cardiomyopathyb
Hypertrophic
cardiomyopathyb
aUsually benign.
bInfrequent, but not benign.
cGenerally not benign.
Table 2 Structural heart diseases that can lead to syncope
Commonly cause syncope Rarely cause syncope
Ischaemic heart disease Myocarditis
Nonischaemic dilated
cardiomyopathy
Pulmonary embolism
Aortic stenosis Cardiac tamponade
Hypertrophic cardiomyopathy Atrial myxoma
Arrhythmogenic right
ventricular cardiomyopathy
Severe pulmonary
hypertension
(Primary electrophysiological
disorders: long QT
syndrome, short QT
syndrome, Brugada
syndrome,
catecholaminergic
polymorphic ventricular
tachycardia)
Aortic dissection
Congenital heart
disease
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any history of cardiovascular problems in the
individual presenting with syncope may be impor-
tant when attempting to narrow the differential
diagnosis.
However, it is noteworthy that the presence of
structural heart disease per se does not neces-
sarily imply that the syncopal event is caused by
the underlying heart disorder. Patients with an
underlying heart condition can also have rela-
tively benign causes of syncope, such as neuro-
cardiogenic or drug-induced syncope. Drug-
induced syncope can be overlooked, especially
in elderly patients who may be taking a number
of different cardiac medications [11]. Frequently
used drugs amongst patients with heart disease
include beta blockers, diuretics and vasodilators.
All these drugs could alone or in combination
predispose patients to episodes of haemodynamic
compromise due to bradycardia and/or hypoten-
sion in different clinical situations. Furthermore,
the use of antiarrhythmic medications can be
associated with proarrhythmia and syncope, or
even cardiac arrest. A complete medication his-
tory including recently started prescription and
over the counter drugs should therefore always
be obtained.
Mechanisms of syncope in structural heart disease
The most frequent cause of syncope in patients
with structural heart disease are arrhythmias
causing decreased cardiac output, haemodynamic
impairment and a subsequent decrease in cerebral
blood flow [3]. Both bradyarrhythmias and tachy-
cardias can lead to syncope. There are a number of
factors that determine whether or not a tachyar-
rhythmia leads to syncope, including the type of
arrhythmia [12]. In this regard, supraventricular
tachyarrhythmias are generally better tolerated
than VTs and the faster the heart rate during the
arrhythmia, the less well it is tolerated. Patients
with impaired left ventricular ejection fraction are
usually less able to tolerate fast heart rhythms. The
posture of a patient during the onset of the
arrhythmia also has an influence on tolerability.
Finally, the use of vasoactive drugs may adversely
affect the haemodynamic response during tachy-
cardia.
Bradycardia due to sick sinus syndrome or
advanced atrioventricular block is another com-
mon cause of syncope in patients with heart
disease. Interruption of cerebral blood flow for
8–10 s usually produces loss of consciousness,
although briefer pauses can cause near syncope
[7]. In individuals with a pacemaker, a device
malfunction needs to be ruled out.
Other possible causes of cardiogenic syncope
include low output states, for example with either
ischaemic or dilated cardiomyopathy, which can
sometimes be further exacerbated if the patient is
taking vasoactive medications, as is common in
those who have these disorders. Conditions such
as aortic stenosis and severe hypertrophic cardio-
myopathy may cause mechanical outflow obstruc-
tion from the left ventricle, especially during
exertion [13]. However, aortic stenosis can also
cause syncope via inappropriate reflex vasodilata-
tion [6].
Initial evaluation of patients with suspected cardiac syncope
As mentioned above, there are a number of findings
of the medical history, physical examination or
ECG that should alert to the possibility of a cardiac
cause of syncope. A number of studies have been
conducted to determine which factors in the clin-
ical history may predict a serious cause of syncope.
Calkins et al. found that male gender, age over
45 years and no more than two episodes of syncope
predicted either VT or atrioventricular block as the
cause of syncope [14]. In addition, syncope whilst
supine, duration of symptoms less than 4 years
and blurred vision were reported to be independent
predictors of cardiac syncope [15]. Furthermore,
Sheldon et al. demonstrated that male gender and
age at onset of syncope over 35 years predicted VT
as the syncopal cause rather than a neurocardio-
genic aetiology [16].
Clinical risk scores have been developed to predict
the outcome in patients presenting with syncope
[1, 17–19]. Many of these risk scores have key
common factors that increase the risk of a poor
outcome, including abnormal ECG, age above
40 years and history of heart failure or myocardial
infarction, which highlights the importance of
structural heart disease in the prognosis of syn-
cope.
The initial evaluation is therefore critical in
patients with syncope. A clinical history, physical
examination and ECG should always be conducted
if there is suspicion of cardiac syncope. Further
diagnostic work-up is guided by the findings of the
initial evaluation.
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History
The evaluation of syncope begins with a thorough
clinical history. This includes a detailed assess-
ment of the syncopal event including prodromal
symptoms and the immediate aftermath. In partic-
ular patients should be asked how they felt upon
awakening after loss of consciousness as this can
be helpful in differentiating between syncope and
other causes of loss of consciousness, such as
seizures. The absence of prodromal symptoms can
be consistent with syncope due to arrhythmia,
especially bradyarrhythmia. Chest pain, shortness
of breath and tachypalpitations are also indicative
of cardiac syncope. The observations of witnesses
to the event are often helpful.
Physical examination
Soon after the event, a detailed physical examina-
tion should be carried out, including measurement
of blood pressure (both supine and standing). In
particular, the cardiovascular examination should
include evaluation of jugular venous distension,
murmurs or additional heart sounds on cardiac
auscultation and displaced point of maximal
impulse. Carotid artery auscultation should also
be performed for evaluation of bruit and the quality
of the carotid pulse. Lung auscultation should
determine the presence of rales and the respiratory
rate and pattern. The quality of peripheral pulses
needs to be evaluated. A neurological examination
should be performed to assess any abnormalities of
cognition, speech, motor strength, sensation or
visual fields.
ECG
The 12-lead ECG is an important tool in the initial
evaluation of syncope. The ECG can provide infor-
mation about heart rate and rhythm, and the
presence of ongoing ischaemia (T wave changes or
ST depression) or a new infarction (ST elevation). In
addition, the presence of Q waves should be noted
as an indication of a prior myocardial infarction or
a myocardial scar. Changes suggestive of left
ventricular hypertrophy might be present on the
ECG. The QT interval should be measured and
evaluated for abnormally long or short QT inter-
vals. The presence of a delta wave, Brugada
pattern, bundle branch block or atrioventricular
conduction abnormalities should also be noted. It
is important to acknowledge that some of the ECG
changes associated with these disorders may only
be present intermittently and therefore one ECG
may not be enough to rule them out. Arrhythmo-
genic right ventricular cardiomyopathy is a rela-
tively rare disorder with ECG characteristics of T
wave inversion in the anteroseptal leads and epsi-
lon waves.
Blood tests
Whilst blood tests are generally not considered a
valuable part of the diagnosis of syncope, a com-
plete blood count and electrolyte levels should be
measured in most instances. In selected patients, if
there is suspicion of acute ischaemia or infarction,
cardiac biomarkers, preferably a troponin, should
be evaluated. In some cases, more than one tropo-
nin test may be needed to rule out myocardial
infarction. If a pulmonary embolus is suspected,
measurement of D-dimer levels may be helpful.
Echocardiogram
The echocardiogram is a relatively simple noninva-
sive test that can easily be performed at the bedside,
even in the emergency department. This test can
provide useful information, especially if structural
heart disease is suspected or if a patient with known
heart disease presents with syncope. The echocar-
diogram provides a good estimate of left ventricular
function, including signs of regional wall motion
abnormalities that are consistent with coronary
artery disease. In addition, left ventricular size and
thickness are readily visualized by this technique.
The presence of valvular heart disease, including
aortic stenosis, can be evaluated. Tricuspid regur-
gitation, particularly if accompanied by dilatation of
the right ventricle, raises suspicion of a pulmonary
embolus. Right ventricular dilatation and thinning
of the wall may be present in conditions such as
arrhythmogenic right ventricular cardiomyopathy.
ECG monitoring
Individuals with syncope who have evidence of
structural heart disease are candidates for hospital
admission for continuous telemetry. Holter moni-
toring, for 24 h or longer, is frequently used for
further evaluation of heart rate and rhythm in
patients with syncope. The implantable loop recor-
der, a small wireless monitor placed subcutane-
ously in the chest, is becoming increasingly used
for long-term ECG monitoring. Storage of ECG
tracings can be activated either by prespecified
criteria or by the patients during symptoms. This is
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a promising tool for use in those with recurrent
syncope of unknown cause [20]. The battery of the
most recent loop recorders can last for up to
36 months. It is very important when interpreting
the results of rhythm monitoring to correlate
symptoms with the results of the ECG tracings.
Syncope in patients with suspected or known coronary artery
disease
The presence of ischaemic heart disease increases
the risk of syncope being due to ventricular
arrhythmias. This, in particular, applies to indi-
viduals with a left ventricular ejection fraction of
less than 35%–40%. The risk of death in patients
with syncope and coronary artery disease is
directly proportional to the severity of left ventric-
ular dysfunction [5].
The evaluation of patients with syncope who are at
risk of coronary artery disease should include an
evaluation for myocardial ischaemia as well as for
the signs of previous myocardial infarction. The
choice of initial tests may vary according to the
presentation and the level of suspicion of ischae-
mia, but might include exercise stress testing or a
myocardial perfusion imaging study. It is notewor-
thy that syncope can be the only presenting symp-
tom of myocardial infarction in elderly patients.
In patients with coronary artery disease and a
severely depressed ejection fraction (<35%), who
present with syncope, the risk of malignant ar-
rhythmias is such that an implantable cardioverter
defibrillator (ICD) may be indicated regardless of
the perceived aetiology of the event [21]. Even in
the absence of syncope, an ICD has been shown to
improve mortality in this particular group of
patients [22, 23], and therefore invasive electro-
physiology study for risk stratification with regard
to VT is not required. Such a study can, neverthe-
less, help to determine a specific diagnosis,
although in a patient with noninducible arrhyth-
mias a device is still indicated. On the other hand,
if there is a history of coronary artery disease, even
with prior myocardial infarction, but the ejection
fraction is preserved (>35%–40%), a cardiac elec-
trophysiology study may be indicated for further
risk stratification. The prognosis of patients with a
normal electrophysiological result, under these
circumstances, is favourable [24].
An electrophysiology study is performed by plac-
ing catheters in the right-sided chambers of the
heart via venous puncture, usually in the groin.
Programmed stimulation of the ventricles is used
to evaluate the risk of developing VT [25].
Although the induction of monomorphic VT is
considered a definite abnormality, the induction of
ventricular fibrillation is nonspecific. Sinus node
function and atrioventricular conduction are also
tested, but the sensitivity for these abnormalities
is poor [26]. Inducibility of VT is associated with a
high risk of sudden cardiac death whereas non-
inducibility predicts a low risk of sudden cardiac
death [27]. The value of the electrophysiology
study in patients with normal left ventricular
function and no coronary artery disease is rela-
tively low [28].
It is worth noting that ICD-treated patients remain
at risk of syncope because only the risk of sudden
cardiac death is being assessed. This implies the
need for identification of the precise mechanism of
syncope in these patients and specific treatment if
possible [6].
In patients with coronary artery disease, if the
suspicion of a brady- or tachyarrhythmia is high
despite a normal electrophysiological evaluation,
an implantable loop recorder may be considered.
Syncope and nonischaemic dilated cardiomyopathy
Nonischaemic dilated cardiomyopathy, where left
ventricular function is reduced due to reasons
other than as a consequence of coronary artery
disease, can also be associated with syncope.
Likely causes are ventricular arrhythmias, brad-
yarrhythmias and orthostatic hypotension, either
due to a decreased cardiac output or as a side effect
of the medications used to treat the dilated cardio-
myopathy. Syncope is an ominous sign in this
population; in one series, almost half of the
patients presenting with this symptom had died
suddenly within 1 year of presentation [29]. It is
interesting that in this same study, 70% of those
who presented with VT or sudden cardiac death
had a prior syncopal event.
As with ischaemic cardiomyopathy, an ICD is
indicated for those who have an ejection fraction
of less than 35% [21]. However, the data on the
mortality benefit of a defibrillator are not as robust
for nonischaemic as for ischaemic cardiomyopa-
thy. The DEFINITE trial enrolled only patients with
nonischaemic heart failure and, although there
was a significant reduction in sudden death, there
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was only a borderline significant reduction in
overall mortality [30].
Invasive electrophysiology assessment is not as
helpful a risk stratification tool for those with
nonischaemic cardiomyopathy as for those with
coronary artery disease. In a small study of
patients with nonischaemic cardiomyopathy,
unexplained syncope, a normal electrophysiology
study, and who were subsequently treated with an
ICD, 50% received appropriate therapy with a
defibrillator in the first 2 years after implantation
[31]. Thus, the implications of a normal electro-
physiology study in patients with nonischaemic
cardiomyopathy are not as clear as for those with
coronary artery disease and preserved ejection
fraction.
As for patients with ischaemic cardiomyopathy, an
implantable loop recorder may be considered in
those with nonischaemic cardiomyopathy in whom
left ventricular function is relatively preserved
(>35%–40%), when detailed evaluation has not
demonstrated abnormalities, but arrhythmias are
still strongly suspected.
Syncope in hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is a relatively com-
mon (1 : 500) inherited disease that is caused by
mutations in genes encoding sarcomere proteins
[32, 33]. There are different forms of hypertrophy of
the left ventricle, but asymmetric septal hypertro-
phy is the most common. This type involves
primarily the proximal and mid portion of the
interventricular septum. The disease is suspected
if the ECG shows signs of hypertrophy with
inverted T waves in the precordial leads, particu-
larly when the degree of myocardial thickness is
severe. The condition is then confirmed by an
imaging study, usually either echocardiography or
cardiac magnetic resonance imaging (MRI).
In hypertrophic cardiomyopathy, the normal cellu-
lar architecture is disrupted in the hypertrophied
area, and extensive fibrosis (frequently seen as late
gadolinium enhancement on MRI) can increase the
risk of malignant ventricular arrhythmias [34].
This can lead to syncope or even sudden cardiac
death. The occurrence of syncope (particularly
within the previous 6 months) in hypertrophic
cardiomyopathy is serious and increases the risk
of sudden cardiac death five-fold [35]. Other risk
factors for serious arrhythmias include prior his-
tory of resuscitated cardiac arrest, family history
of sudden death, nonsustained VT, marked
(30 mm) hypertrophy and decreased blood pres-
sure with exercise [35]. Invasive electrophysiology
assessment is not particularly helpful for risk
stratification of this condition.
Despite the high risk of ventricular arrhythmias in
hypertrophic cardiomyopathy, syncope in this dis-
order can be caused by a variety of mechanisms.
Individuals with hypertrophic cardiomyopathy are
at increased risk of atrial fibrillation which can
impact the clinical course of the disease [36].
Impaired left ventricular relaxation and heart fail-
ure can result in left atrial enlargement and atrial
fibrillation. The latter is associated with increased
morbidity and mortality due to loss of active
diastolic left ventricular filling and decreased dia-
stolic filling time with rapid ventricular rates.
Patients with severe obstruction of the left ventric-
ular outflow tract may experience syncope during
exercise.
The main treatment for patients at high risk of
sudden death is an ICD. This device is recom-
mended for patients resuscitated from sudden
cardiac death or sustained ventricular tachycar-
dia and is considered a reasonable option if there
is a family history of sudden cardiac death,
maximum wall thickness of 30 mm or recent
unexplained syncope [35]. In those with nonsu-
stained VT or an abnormal blood pressure
response to exercise, an ICD might be useful in
certain circumstances. Beta blockers are fre-
quently prescribed and drugs such as amioda-
rone and disopyramide may also be useful in
certain situations.
Arrhythmogenic right ventricular cardiomyopathy and syncope
Arrhythmogenic right ventricular cardiomyopathy
is a relatively rare disease that is associated with
family clustering and characterized by fibrous and
fatty replacement of the right ventricular myocar-
dium [37]. The fatty/fibrous tissue may be a
substrate for ventricular arrhythmias causing syn-
cope or even sudden cardiac death. Arrhythmo-
genic right ventricular cardiomyopathy usually
affects only the right ventricle although occasion-
ally the left ventricle can also be involved. This
condition may be the cause of up to one-fifth of
sudden deaths in individuals under the age of
35 years [5]. Syncope or sudden death may be the
first manifestation of the disease.
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Arrhythmogenic right ventricular cardiomyopathy
can be difficult to diagnose and the signs are often
subtle. The ECG may show epsilon waves and
inverted T waves in leads V1–V3. An echocardio-
gram may show a dilated and thin-walled right
ventricle. A cardiac MRI usually shows right ven-
tricular dilatation and fatty/fibrous replacement of
the ventricle in addition to localized microaneu-
rysm formation. The role of an electrophysiology
investigation in arrhythmogenic right ventricular
dysplasia remains unclear. It has been shown that
defibrillator therapy can be useful for treatment of
malignant arrhythmias in this condition.
Syncope in aortic stenosis
Aortic stenosis is a disorder of calcific degeneration
of the aortic valve and, with the ageing of Western
populations, has become themost commonvalvular
heart disease inEurope. Syncope is usually a sign of
advanced aortic stenosis. The cause of syncope in
patients with advanced aortic stenosis is likely to be
multifactorial. In general, syncope with aortic ste-
nosis occurs with exercise. It has been presumed
that the reduced degree of valve opening inhibits the
necessary increase in cardiac output whilst periph-
eral vascular resistance falls on exertion. Other
proposed mechanisms include a vasodepressor
response which is triggered by increased left ven-
tricular pressure during exercise in patients with
aortic stenosis [13, 38]. Although severe aortic
stenosis is relatively rare amongst individuals who
present with syncope, it is an important potential
diagnosis and usually suspected after clinical
examination including cardiac auscultation. The
diagnosis is confirmed by echocardiography. The
treatment is, in most cases, valve replacement.
Primary electrophysiological disorders
Although primary electrophysiological disorders
are not in fact structural heart diseases, they are
important causes of cardiac syncope, particularly
in young individuals. These disorders include the
inherited channelopathies, LQTS, short QT syn-
drome and Brugada syndrome. Whilst they can all
be diagnosed with an ECG, the findings may be
subtle and dynamic. Pharmacological provocation
can be helpful if there is suspicion of or Brugada
syndrome, but the ECG does not show typical type
1 changes.
Catecholaminergic polymorphic ventricular tachy-
cardia is most frequent due to an inherited defect
in the ryanodine receptor in cardiac myocytes. This
defect increases the risk of polymorphic VT during
exertion or with elevated heart rates [39]. There are
no distinct abnormalities on the resting ECG, but
polymorphic VT can be seen during an exercise
stress test. An ICD is commonly used to treat high-
risk patients with a primary electrophysiological
disorder.
The future: a role for genetics?
Genetic testing for various disorders that can
cause syncope, including the most common
mutations causing LQTS, has become readily
available. In addition, tests for mutations associ-
ated with Brugada syndrome and catechola-
minergic polymorphic VT have become
commercially available. Testing for sarcomeric
mutations involved in hypertrophic cardiomyopa-
thy and desmosomal protein mutations in ar-
rhythmogenic right ventricular cardiomyopathy is
also possible.
At present, the optimal use of genetic testing in
patients who have survived a cardiac arrest or had
a suspected cardiac syncopal event is still unde-
cided. However, genetic testing has been used
postmortem (molecular autopsy) in cases in which
the apparent cause of sudden death is unknown,
but a primary arrhythmia suspected based on the
clinical circumstances and lack of evidence of
structural heart disease. Recently, in a large series
of unexplained cardiac sudden deaths, genetic
testing achieved a diagnosis in 34% of cases that
would otherwise have remained unexplained [40].
The Heart Rhythm Society and the European
Heart Rhythm Association have recently issued
an expert consensus statement on the use of
genetic testing for channelopathies and cardiomy-
opathies [41]. In this comprehensive document,
the indications for genetic testing for these disor-
ders are reviewed.
There have been further advances in the under-
standing of the potential genetic contribution to
common causes of syncope such as sick sinus
syndrome as well as variants that modulate impor-
tant electrophysiological parameters such as heart
rate, PR interval and QRS duration [42, 43].
Whether or how this will influence future
approaches to common problems such as syncope
remains unclear (Fig. 1), but it is likely that genetic
information will play an increasing role in medical
decision making in the coming decades.
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Summary
In patients who present with syncope, the presence
of structural heart disease should be considered
and further cardiac evaluation performed as indi-
cated by the clinical history, physical examination
and ECG findings. The presence of structural heart
disease in patients with syncope is associated with
a poor prognosis and may be a predictor of sudden
cardiac death. A family history of sudden cardiac
death, especially at a young age, should always be
noted in individuals with syncope, as this may be
an indicator of an inherited disorder that could
lead to life threatening arrhythmias.
Conflict of interest statement
No conflict of interest was declared.
References
1 Ammirati F, Colivicchi F, Santini M. Diagnosing syncope in
clinical practice. Implementation of a simplified diagnostic
algorithm in a multicentre prospective trial – the OESIL 2
study (Osservatorio Epidemiologica della Sincope nel Lazio).
Eur Heart J 2000; 21: 935–940.
2 Brignole M, Menozzi C, Bartoletti A et al. A new management
of syncope: prospective systematic guideline-based evalua-
tion of patients referred urgently to general hospitals. Eur
Heart J 2006; 27: 76–82.
3 Kapoor WN. Syncope. N Engl J Med 2000;343:1856–1862.
4 Soteriades ES, Evans JC, Larson MG et al. Incidence and
prognosis of syncope. N Eng J Med 2002; 347: 878–885.
5 Strickberger SA, Benson DW, Biaggioni I et al. AHA/ACCF
Scientific statement of the evaluation of syncope. Circulation
2006; 113: 316–327.
6 Moya A, Sutton R, Ammirati F et al. Guidelines for the
diagnosis and management of syncope (version 2009). Eur
Heart J 2009; 30: 2631–2671.
7 Stevenson WG. Syncope – getting to the heart of the matter.
N Eng J Med 2002; 347: 931–933.
8 Goldberger JJ, Cain ME, Hohnloser SH et al. AHA/ACCF/
HRS Scientific statement on noninvasive risk stratification
techniques for identifying patients at risk for sudden cardiac
death; a scientific statement from the American Heart Asso-
ciation Council on Clinical Cardiology Committee on Electro-
cardiology and Arrhythmias and Council on Epidemiology
and Prevention. Circulation 2008; 118: 1497–1518.
9 Chang-Sing P, Peter CT. Syncope: evaluation and manage-
ment. A review of current approaches to this multifaceted and
complex clinical problem. Cardiol Clinics 1991; 9: 641–651.
10 Kapoor WN. Evaluation and outcome of patients with syn-
cope. Medicine (Baltimore) 1990;69:160–175.
11 Didyk N, Morillo CA. Falls, dizziness and syncope in the very
old. In: Turpie ID, Heckman GA, eds. Aging Issues in
Cardiology. Norwell, Mass: Kluwer Academic Publishers,
2004; 115–138.
12 Harvey MN, Morady F. Tachyarrhythmias as a cause of
syncope. In: Grubb BP, Olshansky B, eds. Syncope: Mecha-
nisms and Management. Armonk, New York: Futura Publish-
ing Co, 1998; 167–178.
13 Richards AM, Nichols MG, Ikram A, Hamilton EJ, Richards
RD. Syncope in aortic valve stenosis. Lancet 1984; 2: 1113–
1116.
14 Calkins H, Shyr Y, Frumin H, Schork A, Morady F. The value
of the clinical history in differentiation of syncope due to
ventricular tachycardia, atrioventricular block or neurocar-
diogenic syncope. Am J Med 1995; 98: 365–373.
15 Alboni P, Brignole M, Menozzi C et al. Diagnostic value of
history in patients with syncope with or without heart
disease. J Am Coll Cardiol 2001; 37: 1921–1928.
16 Sheldon R, Hersi A, Ritchie D, Koshman ML, Rose S. Syncope
and structural heart disease: historical criteria for vasovagal
syncope and ventricular tachycardia. J Cardiovasc Electro-
physiol 2010; 21: 1358–1364.
17 Quinn J, Mc Dermott D, Stiell I, Kohn M, Wells G. Prospective
validation of the San Francisco syncope rule to predict
patients with serious outcomes. Emerg Med 2006;47:448–
454.
18 Martin TP, Hanusa BH, Kapoor WN. Risk stratification of
patients with syncope. Ann Emerg Med 1997; 29: 459–466.
19 Del Rossi A, Ungar A, Maggi R et al. Clinical predictors of
cardiac syncope at initial evaluation in patients referred
urgently to a general hospital: the EGSYS score. Heart
2008;94:1620–1626.
20 Edvardsson N, Frykman V, Van Mechelen R et al. Use of
implantable loop recorder to increase diagnostic yield in
unexplained syncope: results from the PICTURE registry.
Europace 2011; 13: 262–269.
21 Zipes DP, Camm AJ, Borgrefe M et al. ACC/AHA/ESC 2006
guidelines for ventricular arrhythmias and the prevention
sudden cardiac death – executive summary. Eur Heart
J 2006; 27: 2099–2140.
22 Moss AJ, Zareba W, Hall WJ et al. , for the Multicenter
Automatic Defibrillator Implantation Trial II Investigators.
Prophylactic implantation of a defibrillator in patients with
myocardial infarction and a reduced ejection fraction. N Eng
J Med 2002; 21: 877–883.
Syncope
History, physical examination, electrocardiogram
Echocardiogram, exercise test, Holter monitoring
Event monitor or implantable loop recorder
Non diagnosticDiagnostic
R721W
Diagnostic Unexplained syncope
No further work-up unless additional episodes
Genetic Testing?
Fig. 1 Will genetic testing eventually become a useful tool
in the evaluation of patients with syncope?
D. O. Arnar Review: Syncope in heart disease
ª 2013 The Association for the Publication of the Journal of Internal Medicine 343
Journal of Internal Medicine, 2013, 273; 336–344
23 Bardy GH, Lee KL, Mark DB et al. , for the Sudden Cardiac
Death in Heart Failure Trial (SCD-HeFT) Investigators. Ami-
odarone or an implantable cardioverter defibrillator for con-
gestive heart failure. N Eng J Med 2005; 352: 225–237.
24 Menozzi C, Brignole M, Garcia-Civera R et al. Mechanism of
syncope in patients with heart disease and negative electro-
physiologic test. Circulation 2002; 105: 2741–2745.
25 Fujimura O, Yee R, Klein GJ, Sharma AD, Boahene KA. The
diagnostic sensitivity of electrophysiologic testing in patients
with syncope caused by transient bradycardia. N Eng J Med
1989; 321: 1703–1707.
26 Horowitz LN, Kay HR, Kutalek SP et al. Risks and complica-
tions of clinical electrophysiologic studies: a prospective
analysis of 1000 consecutive patients. J Am Coll Cardiol
1987; 26: 555–573.
27 Olshansky B, Mazuz M, Martins JB. Significance of induced
ventricular tachycardia in patients with syncope of unknown
origin: a long term follow up study. J Am Coll Cardiol 1985; 5:
216–223.
28 Sagerista-Sauleda J, Romero-Ferrer B, Moya A, Permanyer-
Miralda G, Soler-Soler J. Variations in the diagnostic yield of
head-up tilt test and electrophysiology study in groups of
patients with syncope of unknown origin. Eur Heart J 2001;
22: 857–865.
29 Middlekauf HR, Stevenson WG, Stevenson LW, Saxon LA.
Syncope in advanced heart failure: high risk of sudden death
regardless of origin of syncope. J Am Coll Cardiol 1993; 21:
110–116.
30 Kadish A, Dyer A, Daubert JP et al. , for the defibrillators in
non ischemic cardiomyopathy treatment evaluation investi-
gators. Prophylactic defibrillator implantation in patients
with non ischemic dilated cardiomyopathy. N Eng J Med
2004; 350: 2151–2158.
31 Knight BP, Goyal R, Pelosi F et al. Outcome of patients with
nonischemic dilated cardiomyopathy treated with an implant-
able defibrillator. J Am Coll Cardiol 1999; 33: 1964–1970.
32 Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT,
Bild DE. Prevalence of hypertrophic cardiomyopathy in a
general population of young adults: echocardiographic anal-
ysis of 4111 in the CARDIA study. Coronary artery risk
development in (young) adults. Circulation 1995; 92: 795–
799.
33 Alcalai R, Seidman JG, Seidman CE. Genetic basis of hyper-
trophic cardiomyopathy: from bench to clinics. J Cardiovasc
Electrophysiol 2008; 19: 104–110.
34 Spiro P, Autore C, Rapezzi C et al. Syncope and risk of sudden
cardiac death in hypertrophic cardiomyopathy. Circulation
2009; 119: 1703–1710.
35 Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA
guideline for the diagnosis and treatment of hypertrophic
cardiomyopathy: executive summary: a report of the Ameri-
can College of Cardiology Foundation/American Heart Asso-
ciation task force on practice guidelines. Circulation 2011;
124: 2761–2796.
36 Olivotto I, Cecci F, Casey SA et al. Impact of atrial fibrillation
on the clinical course of hypertrophic cardiomyopathy.
Circulation 2001; 104: 2517–2524.
37 Nasir K, Bomma C, Tandri H et al. Electrocardiographic
features of arrhythmogenic right ventricular dysplasia/car-
diomyopathy according to disease severity: a need to broaden
the diagnostic criteria. Circulation 2004; 110: 1527–1534.
38 Lombard JT, Selzer A. Valvular aortic stenosis: a clinical and
hemodynamic profile of patients. Ann Intern Med 1987; 106:
292–298.
39 Bauce B, Rampazzo A, Basso C et al. Screening for ryanodine
receptor type 2 mutations in families with effort-induced
polymorphic ventricular arrhythmias and sudden death:
early diagnosis of asymptomatic carriers. J Am Coll Cardiol
2002; 40: 341–349.
40 Tester DJ, Ackerman MJ. Postmortem long QT syndrome
genetic testing for sudden unexplained death in the young.
J Am Coll Cardiol 2007; 49: 240–246.
41 Ackerman MJ, Priori SG, Willems S et al. HRS/EHRA con-
sensus statement on the state of genetic testing for channel-
opathies and cardiomyopathies: this document was
developed as a partnership between the Heart Rhythm
Society (HRS) and the European Heart Rhythm Association
(EHRA). Heart Rhythm 2011; 13: 1077–1109.
42 Holm H, Gudbjartsson DF, Sulem P et al. A rare variant in
MYH6 is associated with high risk of sick sinus syndrome.
Nat Genet 2011; 43: 316–320.
43 Holm H, Gudbjartsson DF, Arnar DO et al. Several common
variants modulate heart rate, PR interval and QRS duration.
Nat Genet 2010; 42: 117–122.
Correspondence: David O. Arnar MD PhD, EMPH, Division of
Cardiology, Office 14F, Department of Internal Medicine, Land-
spıtali – The National University Hospital of Iceland, Hringbraut,
101 Reykjavik, Iceland.
(fax: +354 543 6467; e-mail: davidar@landspitali.is).
D. O. Arnar Review: Syncope in heart disease
344 ª 2013 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine, 2013, 273; 336–344
